Does a mandatory non-medical switch from originator to biosimilar etanercept lead to increase in healthcare use and costs?

Bente Glintborg*, Rikke Ibsen, Rebecca Elisabeth Qwist Bilbo, Merete Lund Hetland, Jakob Kjellberg

*Corresponding author for this work
8 Citations (Scopus)
1 Downloads (Pure)

Fingerprint

Dive into the research topics of 'Does a mandatory non-medical switch from originator to biosimilar etanercept lead to increase in healthcare use and costs?'. Together they form a unique fingerprint.

Keyphrases

Nursing and Health Professions

Medicine and Dentistry

Pharmacology, Toxicology and Pharmaceutical Science